You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
FormFactor registered 2,234,887 common shares for Teradyne’s resale after Teradyne bought them for approximately $300.0 million in a private placement that closed November 9, 2026. FormFactor will receive no resale proceeds.
Teradyne, Inc. may resell up to 2,234,887 FormFactor common shares purchased for approximately $300.0 million in a private placement that closed on November 9, 2026; FormFactor will receive no resale proceeds.
FormFactor, Inc. generated net income of $150.4 million in the first nine months of fiscal 2026, compared to $31.1 million in fiscal 2025, as record quarterly revenue and improved gross margins drove the increase. Restructuring charges partially offset the gains.
FormFactor reported Q3 revenue of $280.5 million, up close to 40% year over year, with non-GAAP gross margin of 56.5% and fully diluted EPS of $1.04.
FormFactor reported third-quarter fiscal 2026 revenue of $280.5 million, GAAP net income of $73.8 million and gross margin of 54.7%, and guided fourth-quarter revenue to $285 million +/- $10 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. FormFactor posted record Q2 revenue of $258.2M and non-GAAP gross margin of 53.3%, surpassing the high end of guidance, and guided Q3 revenue to $270M with non-GAAP EPS of $0.86. Management raised 2026 co-packaged optics revenue to exceed the prior $10–20M range and highlighted progress toward its 2030 target model, including the Farmers Branch capacity ramp beginning Q4.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average debt outstanding | 11.7M | the three months ended June 27, 2026 filing | — |
| Revenue growth from HBM products as a share of year-over-year increase in DRAM product revenues | 75% | the three months ended June 27, 2026 filing | — |
| Weighted average balance of cash and investments | 335.1M | the three months ended June 27, 2026 filing | — |
| Weighted average interest rate on debt | 2.75% | the three months ended June 27, 2026 filing | — |
| Weighted average yield on cash and investments | 3.79% | the three months ended June 27, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FORM
this stock
Formfactor Inc
|
$6.86B | +56.9% | +2.8% | 40.0 | 3.6% |
|
ASML
Asml Holding NV
|
$576.26B | +39.8% | — | — | 0.3% |
|
AMAT
Applied Materials Inc
|
$294.03B | +44.2% | -12.6% | 32.0 | 1.8% |
|
LRCX
Lam Research Corp
|
$282.21B | +32.0% | +51.7% | 33.7 | 2.2% |
|
KLAC
Kla Corp
|
$198.47B | — | +11.7% | 38.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
FormFactor registered 2,234,887 common shares for Teradyne’s resale after Teradyne bought them for approximately $300.0 million in a private placement that closed November 9, 2026. FormFactor will receive no resale proceeds.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FORM | +7.9% | -16.7% | -35.9% | +0.0% | +56.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +5.3% | -15.5% | -36.4% | +0.2% | +46.3% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
